Logo image of MKEA.PA

MAUNA KEA TECHNOLOGIES (MKEA.PA) Stock Fundamental Analysis

EPA:MKEA - Euronext Paris - Matif - FR0010609263 - Common Stock - Currency: EUR

0.62  0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MKEA. MKEA was compared to 57 industry peers in the Health Care Equipment & Supplies industry. MKEA may be in some trouble as it scores bad on both profitability and health. MKEA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MKEA has reported negative net income.
MKEA had a negative operating cash flow in the past year.
MKEA had negative earnings in each of the past 5 years.
In the past 5 years MKEA always reported negative operating cash flow.
MKEA.PA Yearly Net Income VS EBIT VS OCF VS FCFMKEA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

The profitability ratios for MKEA are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MKEA.PA Yearly ROA, ROE, ROICMKEA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

Looking at the Gross Margin, with a value of 9.79%, MKEA is doing worse than 86.21% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MKEA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 9.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MKEA.PA Yearly Profit, Operating, Gross MarginsMKEA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

More info and screens

1

2. Health

2.1 Basic Checks

MKEA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for MKEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MKEA.PA Yearly Shares OutstandingMKEA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
MKEA.PA Yearly Total Debt VS Total AssetsMKEA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -2.19, we must say that MKEA is in the distress zone and has some risk of bankruptcy.
MKEA's Altman-Z score of -2.19 is on the low side compared to the rest of the industry. MKEA is outperformed by 87.93% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.19
ROIC/WACCN/A
WACC6.43%
MKEA.PA Yearly LT Debt VS Equity VS FCFMKEA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M

2.3 Liquidity

MKEA has a Current Ratio of 1.19. This is a normal value and indicates that MKEA is financially healthy and should not expect problems in meeting its short term obligations.
MKEA has a worse Current ratio (1.19) than 75.86% of its industry peers.
MKEA has a Quick Ratio of 1.19. This is a bad value and indicates that MKEA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.94, MKEA is not doing good in the industry: 63.79% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.94
MKEA.PA Yearly Current Assets VS Current LiabilitesMKEA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

2

3. Growth

3.1 Past

MKEA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.86%, which is quite impressive.
MKEA shows a decrease in Revenue. In the last year, the revenue decreased by -2.87%.
The Revenue has been growing slightly by 2.26% on average over the past years.
EPS 1Y (TTM)28.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.82%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y0.21%
Revenue growth 5Y2.26%
Sales Q2Q%-6.79%

3.2 Future

The Earnings Per Share is expected to grow by 72.59% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -2.76% on average over the next years.
EPS Next Y-62.13%
EPS Next 2Y72.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-18.48%
Revenue Next 2Y-2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MKEA.PA Yearly Revenue VS EstimatesMKEA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MKEA.PA Yearly EPS VS EstimatesMKEA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MKEA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MKEA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MKEA.PA Price Earnings VS Forward Price EarningsMKEA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MKEA.PA Per share dataMKEA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as MKEA's earnings are expected to grow with 72.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.59%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MKEA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAUNA KEA TECHNOLOGIES

EPA:MKEA (8/7/2023, 7:00:00 PM)

0.62

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap28.74M
Analysts87.5
Price Target1.99 (220.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-338.12%
EPS NY rev (3m)-338.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-32.43%
Revenue NY rev (3m)-32.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.16
BVpS-0.43
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 9.79%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 0.94
Altman-Z -2.19
F-Score2
WACC6.43%
ROIC/WACCN/A
Cap/Depr(3y)48.95%
Cap/Depr(5y)75.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.82%
EPS Next Y-62.13%
EPS Next 2Y72.59%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y0.21%
Revenue growth 5Y2.26%
Sales Q2Q%-6.79%
Revenue Next Year-18.48%
Revenue Next 2Y-2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-833.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.06%
OCF growth 3YN/A
OCF growth 5YN/A